Search results
Results from the WOW.Com Content Network
Policymakers especially viewed the coronavirus vaccines developed by Pfizer, Johnson & Johnson, and Moderna — which each spent substantial amounts of money lobbying the federal government in ...
Stocks of coronavirus vaccine could run out at the end of January unless new ones such as the Oxford jab are approved, a former minister has warned. Former health secretary Jeremy Hunt told the ...
The company — which expects its 2023 revenus to be at least $6 billion — reported $1.8 billion in COVID-19 vaccine sales in the third quarter and $3.9 billion through Q3.
COVID-19 vaccines gave Moderna, Pfizer and Johnson & Johnson a boost — but are the stocks still a good investment in 2021? Here's what to consider before buying in.
Percent of people of all ages who received all doses prescribed by the initial COVID-19 vaccination protocol. Two of the three COVID-19 vaccines used in the U.S. require two shots to be fully vaccinated. The other vaccine requires only one shot. Booster doses are recommended too. [2] [3] See Commons source for date of last upload.
An hour before the market closed Thursday, as news reports of Trump’s choice began trickling out, Covid-19 vaccine maker Moderna dipped as much as 6%, and Pfizer fell almost 2%.
On July 22, 2020, the U.S. government placed a conditional advance-purchase order of $2 billion with Pfizer to manufacture 100 million doses of a COVID-19 vaccine, with an option for 500 million more, for use in the United States if the vaccine was shown to be safe, effective, licensed, and authorized by the Food and Drug Administration (FDA).
For example, a global fund can guarantee to pay $14 out of $15 for the first 200 million doses of vaccines that have an efficacy of more than 70%. Countries benefiting from the vaccines agree to pay the remaining part of the price ($1 in the example). This small co-payment ensures that there is an actual demand for the vaccines.